Avalo Therapeutics, Inc. (AVTX)
19.34
-0.25
(-1.28%)
USD |
NASDAQ |
Aug 31, 16:00
18.86
-0.48
(-2.48%)
After-Hours: 04:52
Avalo Therapeutics Total Long Term Debt (Quarterly) : 2.00M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.00M |
| March 31, 2026 | 2.00M |
| December 31, 2025 | 2.035M |
| September 30, 2025 | 2.117M |
| June 30, 2025 | 2.197M |
| March 31, 2025 | 2.275M |
| December 31, 2024 | 2.35M |
| September 30, 2024 | 1.083M |
| June 30, 2024 | 1.183M |
| March 31, 2024 | 1.281M |
| December 31, 2023 | 3.366M |
| September 30, 2023 | 1.456M |
| June 30, 2023 | 15.66M |
| March 31, 2023 | 21.40M |
| December 31, 2022 | 23.13M |
| September 30, 2022 | 19.07M |
| June 30, 2022 | 22.58M |
| March 31, 2022 | 37.13M |
| December 31, 2021 | 36.85M |
| September 30, 2021 | 35.46M |
| June 30, 2021 | 20.14M |
| March 31, 2021 | 3.018M |
| December 31, 2020 | 3.038M |
| September 30, 2020 | 3.094M |
| Date | Value |
|---|---|
| June 30, 2020 | 3.192M |
| March 31, 2020 | 1.094M |
| September 30, 2019 | 16.43M |
| June 30, 2019 | 16.54M |
| March 31, 2019 | 16.54M |
| December 31, 2018 | 15.38M |
| September 30, 2018 | 15.40M |
| June 30, 2018 | 15.43M |
| March 31, 2018 | 15.38M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.6076M |
| March 31, 2017 | 1.492M |
| December 31, 2016 | 2.354M |
| September 30, 2016 | 3.190M |
| June 30, 2016 | 4.002M |
| March 31, 2016 | 4.792M |
| December 31, 2015 | 5.562M |
| September 30, 2015 | 6.324M |
| June 30, 2015 | 7.053M |
| March 31, 2015 | 7.26M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Incyte Corp. | 32.68M |
| AbbVie, Inc. | 70.82B |
| Rezolute, Inc. | 0.438M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |